Cancer Science & Therapy

Sidén Åke

Publications

• Research Article
  Regrowth Concentration Zero (RC0) as Complementary Endpoint Parameter to Evaluate Compound Candidates During Preclinical Drug Development for Cancer Treatment
  Author(s): Avramidis Dimitrios, Cruz Mabel, Sidén Åke, Tasat Deborah Ruth and Yakisich J. SebastianAvramidis Dimitrios, Cruz Mabel, Sidén Åke, Tasat Deborah Ruth and Yakisich J. Sebastian
  
  The screening process for potential anticancer drugs involves expensive and time consuming preclinical and clinical trials (CT) before a drug is approved for clinical use (CU). At present, there is a “bottleneck” at the CT/CU transition because many drugs that showed promising results during preclinical research did not pass clinical trials. We speculated that the endpoint parameters (the inhibitory concentration 50 (IC50) or lethal concentration 100 (CL100)) commonly used in proliferation assays for short-term periods (24-72 h) are not useful to predict the antiproliferative effect in vivo, especially during clinical trials. We propose the use of a parameter, regrowth concentration 0 (RC0), which will define the concentration and time necessary to kill 100 % of the cells and prevent regrowth when drug is removed. The RC0 might introduce a new bottleneck at the preclinical.. Read More»
  DOI: 10.4172/1948-5956.1000003

  Abstract PDF